CD19/CD22 CAR-T Cell Therapy(Guangzhou Women And Children'S Medical Center)

N/A

Report date: 2025/04/03 16:59:26

Base Information

Drug NameCD19/CD22 CAR-T Cell Therapy(Guangzhou Women And Children'S Medical Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsAnti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Women And Children'S Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Women And Children'S Medical Center
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A